PEG-MGF
Pegylated Mechano Growth Factor | IGF-1 Splice Variant
PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of the IGF-1 splice variant MGF (IGF-1Ec), with polyethylene glycol attached to extend its half-life from minutes to hours. MGF is naturally expressed in muscle tissue following mechanical stress or injury, where it activates satellite cells to support muscle repair. A landmark 2011 human cell study (cited 74+ times) showed MGF significantly increased satellite cell proliferation at doses as low as 3ng/ml, with effects on proliferative lifespan in young but not elderly donors. While in vitro and animal studies show promise for muscle regeneration, tissue repair, and neuroprotection, human clinical research remains limited. PEG-MGF is not FDA-approved and is classified as a research chemical.
Daily dose
200-400mcg
Frequency
2-3 times weekly
Cycle length
4-8 weeks
Storage
2-8°C (reconstituted)
Key benefits
Extended half-life (hours vs minutes for unmodified MGF) through PEGylation. Activates satellite cells for muscle repair and regeneration. May support recovery from mechanical stress or injury.
How it works
PEG-MGF activates muscle satellite (stem) cells by binding to specific receptors, stimulating the MAPK/ERK signaling pathway. This enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain appears to have distinct activity from mature IGF-1.
Dosage protocols
Goal
General Recovery Protocol
Dose
200mcg · 2-3 times weekly
Route
Subcutaneous or intramuscular
Goal
Targeted Muscle Recovery
Dose
200-400mcg · Post-workout, 2-3 times weekly
Route
Intramuscular (bilateral, near target muscle)
Goal
Injury Recovery Protocol
Dose
200-400mcg · 2-3 times weekly
Route
Intramuscular near injury site
Goal
Conservative Research Protocol
Dose
100-200mcg · 2 times weekly
Route
Subcutaneous
Research indications
muscle Repair
tissue Regeneration
recovery
neuroprotection
Administration
Interactions
Safety notes
Not FDA-approved - research chemical only with limited human safety data
Contraindicated with any history of cancer or neoplastic disease
Discontinue if any unusual growths, lumps, or tissue changes occur
Long-term safety profile is unknown
May affect blood glucose - monitor if diabetic or pre-diabetic
Not recommended during pregnancy or breastfeeding
Prohibited in competitive sports (WADA banned substance)
Age-dependent response: Human cell studies showed proliferative benefits in young (≤15yr) but NOT elderly (73yr) satellite cells
May deplete reserve cell population - hypertrophy was associated with decreased reserve cells in studies
Research studies
MGF Inflammatory Response Study (Doroudian et al., 2018)
Mouse muscle injury model | MGF overexpression | 14 days | Macrophage analysis
MGF overexpression modulated inflammatory cytokine expression and enhanced macrophage resolution during skeletal muscle injury recovery. Suggests MGF plays role in coordinating inflammatory-to-regenerative phase transition.
View study →MGF-E Peptide Human Muscle Cell Study (Kandalla et al., 2011)
Human satellite cells | In vitro | Neonatal, 15yr, 73yr donors | Doses: 3-100ng/ml
Landmark study testing MGF-24aa-E peptide on human satellite cells from different ages. Found significant cell proliferation increase even at 3ng/ml (P<0.001), with 100ng/ml showing largest effect. MGF increased proliferative lifespan and delayed senescence in neonatal and young adult cells, but NOT in old adult (73yr) cells. Hypertrophy with decreased reserve cells observed in ALL age groups. Authors concluded MGF could combat sarcopenia without IGF-1 oncogenic side effects.
View study →Human Myoblast Migration & Transplantation (Mills et al., 2007)
Human cells | In vivo | MGF-24aa-E peptide | Cell transplantation
MGF-24aa-E peptide was shown to favor in vivo migration of human myoblasts and improve human precursor cell transplantation outcomes, suggesting applications for cell-based therapies.
MGF Neuroprotection Study (Dluzniewska et al., 2005)
Neuronal tissue | MGF treatment | Oxidative stress model | Cell survival
Studies demonstrated MGF protects against oxygen free radical damage and has special functions in damage, repair and adaptation in neuronal tissue, suggesting potential applications beyond muscle.
Rat Disc Degeneration Model
Rats | PEG-MGF supplementation | Mechanical disc degeneration | Muscle wasting outcome
PEG-MGF supplementation slowed progression of muscle wasting associated with mechanically-induced disc degeneration in rat models.
Achilles Tendon Healing Study
Rats | PEG-MGF treatment | Tendon injury model | Healing assessment
PEG-MGF treatment improved healing outcomes of injured Achilles tendons in rat models, suggesting potential applications for tendon repair.
Rabbit Bone Regeneration Study
Rabbits | PEG-MGF treatment | Bone injury model | Osteoblast regulation
PEG-MGF treatment resulted in faster bone healing by regulating the activity of bone-forming cells (osteoblasts) in rabbit models.
Articular Cartilage Repair Study
Rabbits | PEG-MGF treatment | Cartilage injury model | Repair assessment
Rabbit models showed PEG-MGF significantly improved articular cartilage repair outcomes, indicating potential for joint regeneration research.